000			01985 a2200553 4500
005			20250515221838.0
264		0	_c20100519
008			201005s 0 0 fre d
022			_a1769-6917
024	7		_a10.1684/bdc.2010.1067 _2doi
040			_aNLM _beng _cNLM
100	1		_aAlbouy, B
245	0	0	_a[Renal cell carcinoma management and therapies in 2010]. _h[electronic resource]
260			_bBulletin du cancer _c2010
300			_a17-28 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAntibodies, Monoclonal _xtherapeutic use
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aBenzenesulfonates _xtherapeutic use
650	0	4	_aBevacizumab
650	0	4	_aCarcinoma, Renal Cell _xdrug therapy
650	0	4	_aChemotherapy, Adjuvant
650	0	4	_aCombined Modality Therapy
650	0	4	_aEverolimus
650	0	4	_aHumans
650	0	4	_aIndoles _xtherapeutic use
650	0	4	_aInterferons _xtherapeutic use
650	0	4	_aInterleukin-2 _xtherapeutic use
650	0	4	_aIntracellular Signaling Peptides and Proteins _xantagonists & inhibitors
650	0	4	_aKidney Neoplasms _xdrug therapy
650	0	4	_aMetabolic Networks and Pathways _xdrug effects
650	0	4	_aNephrectomy
650	0	4	_aNiacinamide _xanalogs & derivatives
650	0	4	_aPhenylurea Compounds
650	0	4	_aProtein Serine-Threonine Kinases _xantagonists & inhibitors
650	0	4	_aPyridines _xtherapeutic use
650	0	4	_aPyrroles _xtherapeutic use
650	0	4	_aSirolimus _xanalogs & derivatives
650	0	4	_aSorafenib
650	0	4	_aSunitinib
650	0	4	_aTOR Serine-Threonine Kinases
650	0	4	_aVascular Endothelial Growth Factor A _xmetabolism
700	1		_aGross Goupil, M
700	1		_aEscudier, B
700	1		_aMassard, C
773	0		_tBulletin du cancer _gvol. 97 _gp. 17-28
856	4	0	_uhttps://doi.org/10.1684/bdc.2010.1067 _zAvailable from publisher's website
999			_c19775458 _d19775458